tetracycline and Anthrax

Multifunctional fluorescent probes have received increasing attention for the sake of atom economy and high-density integration. Herein, CdTe quantum dots (QDs) modified with Eu

Topics: Anthrax; Anti-Bacterial Agents; Biomarkers; Cadmium Compounds; Fluorescent Dyes; Humans; Quantum Dots; Spectrometry, Fluorescence; Spores; Tellurium; Tetracycline

There are few options for prophylaxis after exposure to Bacillus anthracis, especially in children and women of childbearing potential. Faropenem is a beta-lactam in the penem subclass that is being developed as an oral prodrug, faropenem medoxomil, for the treatment of respiratory tract infections. Faropenem was shown to have in vitro activity against B. anthracis strains that variably express the bla1 beta-lactamase (MIC range,

Topics: Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; beta-Lactamases; beta-Lactams; Blood Proteins; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Inhalation Exposure; Mice; Mice, Inbred BALB C; Models, Biological

The efficiency of postexposure prophylaxis against Bacillus anthracis infection was tested in guinea pigs infected intranasally with either Vollum or strain ATCC 6605 spores (75 times the 50% lethal dose [LD(50)] and 87 times LD(50,) respectively). Starting 24 h postinfection, animals were treated three times per day for 14 days with ciprofloxacin, tetracycline, erythromycin, cefazolin, and trimethoprim-sulfamethoxazole (TMP-SMX). Administration of cefazolin and TMP-SMX failed to protect the animals, while ciprofloxacin, tetracycline, and erythromycin prevented death. Upon cessation of treatment all erythromycin-treated animals died; of the tetracycline-treated animals, two of eight infected with Vollum and one of nine infected with ATCC 6605 survived; and of the ciprofloxacin group injected with either 10 or 20 mg/kg of body weight, five of nine and five of five animals, respectively, survived. To test the added value of extending the treatment period, Vollum-infected (46 times the LD(50)) animals were treated for 30 days with ciprofloxacin or tetracycline, resulting in protection of eight of nine and nine of nine animals, respectively. Once treatment was discontinued, only four of eight and five of nine animals, respectively, survived. Following rechallenge (intramuscularly) of the survivors with 30 times the LD(50) of Vollum spores, all ciprofloxacin-treated animals were protected while none of the tetracycline-treated animals survived. In an attempt to confer protective immunity lasting beyond the termination of antibiotic administration, Vollum-infected animals were immunized with a protective antigen (PA)-based vaccine concurrently with treatment with either ciprofloxacin or tetracycline. The combined treatment protected eight of eight and nine of nine animals. Following cessation of antibiotic administration seven of eight and eight of eight animals survived, of which six of seven and eight of eight resisted rechallenge. These results indicate that a combined treatment of antibiotics together with a PA-based vaccine could provide long-term protection to prevent reoccurrence of anthrax disease.

Topics: Animals; Anthrax; Anthrax Vaccines; Bacillus anthracis; Ciprofloxacin; Female; Guinea Pigs; Microbial Sensitivity Tests; Spores, Bacterial; Tetracycline; Vaccination

In vivo and in vitro efficacy of tetracyclines was studied with respect to anthracic infection induced by a tetracycline-resistant resistant strain containing plasmid pBC16. The plasmid-containing strain was resistant to tetracycline, doxycycline and minocycline, the MICs exceeding those for the initial strain 500, 640 and 80 times, respectively. There was no therapeutic effect of tetracycline and doxycycline in the treatment and urgent prophylaxis of anthracic infection caused by the tetracycline-resistant strain of Bacillus anthracis. High therapeutic efficacy of minocycline in the average therapeutic concentrations was shown irrespective of the contaminating doses and strains. Minocycline was recommended for treatment and urgent prophylaxis of anthracic infection caused by tetracycline-resistant B. anthracis strains.

Topics: Animals; Anthrax; Bacillus anthracis; Cricetinae; Disease Models, Animal; Doxycycline; Drug Resistance, Microbial; Genes, Bacterial; In Vitro Techniques; Mesocricetus; Mice; Minocycline; R Factors; Tetracycline; Tetracycline Resistance

Topics: Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Chloramphenicol; Chlortetracycline; Humans; Kanamycin; Mice; Microbial Sensitivity Tests; Oxytetracycline; Penicillins; Streptomycin; Tetracycline

Two patients contracted cutaneous anthrax after contact with infected bone meal. Awareness of the risk of infection from this source may help in achieving early clinical diagnosis and a low fatality rate following effective antibiotic therapy.

Topics: Anthrax; Bacillus anthracis; Fertilizers; Humans; Male; Middle Aged; Penicillins; Skin Diseases, Infectious; Streptomycin; Tetracycline

Topics: Amphotericin B; Animals; Anthrax; Anti-Bacterial Agents; Child; Communicable Disease Control; Epidemiology; Erythromycin; Ethylenediamines; Humans; Massachusetts; Occupational Diseases; Penicillin G; Penicillin G Benzathine; Penicillin G Procaine; Penicillins; Polymyxins; Procaine; Tetracycline; Textile Industry; Vaccination; Wool; Zoonoses

Topics: Anthrax; Anti-Bacterial Agents; Humans; Meat; Penicillins; Sulfonamides; Tetracycline

Topics: Animals; Anthrax; Anti-Bacterial Agents; Haplorhini; Humans; Penicillin Resistance; Penicillins; Protein Synthesis Inhibitors; Radiography, Thoracic; Research; Respiratory Tract Infections; Tetracycline

Topics: Animals; Anthrax; Anti-Bacterial Agents; Sheep; Sheep Diseases; Tetracycline

Topics: Anthrax; Anti-Bacterial Agents; Chlortetracycline; Erythromycin; Humans; Oxytetracycline; Protein Synthesis Inhibitors; Tetracycline